NSE / BSEHealthcare
β‚Ή1104.35-26.15-2.31%
P/E20.3Mkt Capβ‚Ή10.78 K CrEV/EBITDA15.2

ALIVUS LIFE SCIENCES LIMITED

P/E20.3Mkt Capβ‚Ή10.78 K CrEV/EBITDA15.2
Company Profile

Alivus Life Sciences Limited develops, manufactures, and markets active pharmaceutical ingredients in India, Japan, Europe, North and Latin America, and internationally. It offers various APIs, such as olmesartan, telmisartan, solifenacin, sitagliptin, zonisamide, rosuvastatin, amiodarone, ezetimibe, lithium carbonate, oxcarbazepine, mirabegron, atovaquone, etoricoxib, remogliflozin, cabozantinib, and palbociclib for various therapeutic areas, including cardiovascular disease, central nervous system disorders, diabetes, gastrointestinal health, oncology, pain management, immunosuppressant, respiratory and ophthalmologic agents, urology, and anti-infectives. The company also provides contract development and manufacturing services to a range of multinational corporations and specialty companies. It exports its products. The company was formerly known as Glenmark Life Sciences Limited and changed its name to Alivus Life Sciences Limited in December 2024. The company was founded in 2001 and is based in Mumbai, India. Alivus Life Sciences Limited is a subsidiary of Nirma Limited.

Valuation

Market Cap
β‚Ή0.00
β€”
Current Price
β‚Ή0
β€”as of 28 Jul 2026
P/E Ratio
0.0x
β€”
P/B Ratio
0.0x
β€”
EV / EBITDA
0.0x
β€”
EV / Sales
0.0x
β€”
52W High
β‚Ή0
β€”
52W Low
β‚Ή0
β€”
Shares Out
0.00 Cr
β€”

Profitability

Operating Margin
0.0%
β€”
Net Profit Margin
0.0%
β€”
EBITDA Margin
0.0%
β€”

Returns

ROE
0.0%
β€”
ROCE
0.0%
β€”
ROIC %
β€”
β€”
ROA
0.0%
β€”
Dividend Payout
0.0%
β€”

Solvency

Current Ratio
0.0x
β€”
Debt / Equity
0.0x
β€”
Debt / Assets
0.0x
β€”
CFO / Net Profit
0.0x
β€”
Interest Coverage
0.0x
β€”

AI Summary

Indian Stock

Sign up free to view AI insights

Get Started

Rule-based from financial data. Not advice.

Price Historyβ–² 7.48% over 1Y
Monthly Returns

Historically, Apr has averaged the highest return (+9.5%); Feb the lowest (-11.0%).

Average from:
YearJanFebMarAprMayJunJulAugSepOctNovDec
2026+4.8%Positive MonthJan 2026: +4.81%-5.0%Negative MonthFeb 2026: -5.02%+6.7%Positive MonthMar 2026: +6.69%+6.5%Positive MonthApr 2026: +6.50%-0.1%Neutral MonthMay 2026: -0.15%+11.6%Positive MonthJun 2026: +11.59%-4.5%*Negative MonthJul 2026: -4.47%β€”β€”β€”β€”β€”
2025+22.3%Positive MonthJan 2025: +22.32%-26.3%Negative MonthFeb 2025: -26.33%+21.9%Positive MonthMar 2025: +21.91%+1.7%Neutral MonthApr 2025: +1.67%-4.8%Negative MonthMay 2025: -4.79%-4.0%Negative MonthJun 2025: -4.05%+2.8%Positive MonthJul 2025: +2.75%-8.3%Negative MonthAug 2025: -8.33%-1.6%Neutral MonthSep 2025: -1.60%-2.5%Negative MonthOct 2025: -2.54%-1.0%Neutral MonthNov 2025: -1.05%+2.3%Positive MonthDec 2025: +2.34%
2024+32.9%Positive MonthJan 2024: +32.86%-0.5%Neutral MonthFeb 2024: -0.50%-10.8%Negative MonthMar 2024: -10.75%+6.9%Positive MonthApr 2024: +6.94%+0.7%Neutral MonthMay 2024: +0.66%+4.2%Positive MonthJun 2024: +4.18%+2.2%Positive MonthJul 2024: +2.15%+19.0%Positive MonthAug 2024: +19.04%+0.1%Neutral MonthSep 2024: +0.10%-0.5%Neutral MonthOct 2024: -0.52%+3.2%Positive MonthNov 2024: +3.20%-9.6%Negative MonthDec 2024: -9.55%
2023-8.0%Negative MonthJan 2023: -8.04%-3.1%Negative MonthFeb 2023: -3.12%+4.5%Positive MonthMar 2023: +4.54%+28.7%Positive MonthApr 2023: +28.73%+6.8%Positive MonthMay 2023: +6.82%+5.7%Positive MonthJun 2023: +5.74%+16.5%Positive MonthJul 2023: +16.50%-4.5%Negative MonthAug 2023: -4.50%-2.5%Negative MonthSep 2023: -2.52%+1.0%Neutral MonthOct 2023: +0.97%+0.9%Neutral MonthNov 2023: +0.91%+4.4%Positive MonthDec 2023: +4.43%
2022-8.9%Negative MonthJan 2022: -8.93%-20.2%Negative MonthFeb 2022: -20.25%+0.1%Neutral MonthMar 2022: +0.14%+3.5%Positive MonthApr 2022: +3.45%-10.8%Negative MonthMay 2022: -10.85%+4.7%Positive MonthJun 2022: +4.72%+4.5%Positive MonthJul 2022: +4.51%-5.1%Negative MonthAug 2022: -5.10%-12.4%Negative MonthSep 2022: -12.37%+10.4%Positive MonthOct 2022: +10.39%+0.6%Neutral MonthNov 2022: +0.60%-1.7%Neutral MonthDec 2022: -1.74%
2021β€”β€”β€”β€”β€”β€”β€”β€”-1.6%Neutral MonthSep 2021: -1.55%-6.8%Negative MonthOct 2021: -6.80%-3.4%Negative MonthNov 2021: -3.45%+3.2%Positive MonthDec 2021: +3.20%
AvgΒ±SD+8.6%Β±16.6%-11.0%Β±10.3%+4.5%Β±10.6%+9.5%Β±9.8%-1.7%Β±5.9%+4.4%Β±5.0%+4.3%Β±6.8%+0.3%Β±10.9%-3.6%Β±4.5%+0.3%Β±5.7%+0.0%Β±2.2%-0.3%Β±5.1%
* Current month β€” value will change until month-end.

Each cell is the percentage change in closing price from the end of the prior month to the end of this month. The bottom row shows the average return for that calendar month across the selected years, plus or minus one standard deviation β€” the range that historically contained roughly two-thirds of outcomes. Past monthly patterns are not a forecast of future returns.

Seasonal Tendency

This aggregates every month by calendar position β€” all Januaries together, all Februaries together, and so on β€” to show whether a given month has leaned positive or negative historically. β€˜Simple’ counts each month as +1 or βˆ’1. β€˜Weighted’ gives larger moves more influence: +2 above +10%, βˆ’2 below βˆ’10%. With only 6 years of history for this asset, each month’s score reflects a small number of observations β€” read it as a historical tendency, not a reliable seasonal pattern.

Historical Trend

This tracks a running tally across the asset’s full price history: each month adds or subtracts based on whether it was positive or negative. A rising line means more positive months than negative so far; a flattening or falling line means recent months have leaned negative. This measures historical month-to-month consistency, not expected future performance.

Year-to-Date ROI
Average from:
SD Γ—
Latest: 1.204x (2026)

Year-to-date return is calculated by dividing each day’s closing price by the price on January 1st of that year (or the asset’s first available price if it began trading mid-year). The custom average line shows the mean YTD return at each calendar day across the selected years. The standard deviation band shows the range within which returns have historically fallen β€” at 1 SD, roughly two-thirds of years; at 2 SD, roughly 95%. Past year-to-date patterns do not predict future returns. The average and standard deviation band are computed from the year set chosen in β€œAverage from”, which is independent of which year lines are displayed. The current in-progress year is excluded from these calculations, since a partial year is not comparable to complete ones. Election-cycle groupings follow the US presidential calendar and are offered only for US and crypto assets.

Historical Performance

Revenue, profitability, and cash flow trends (β‚Ή Crores)

Revenue (10Y)

Operating Income (10Y)

Net Profit (10Y)

Operating Margin % (10Y)

Dividend Payout % (10Y)

Free Cash Flow (10Y)

Growth Summary

Latest fiscal year: Mar 2025

Revenueβ‚Ή2.39 K Crβ–² 4.6%
EBITDA Growthβ€”
Net Profitβ‚Ή486.00 Crβ–² 3.2%
Cash from Ops (CFO)β€”
Free Cash Flow (FCF)β€”β–Ό 1377.8%
Revenue CAGR 5Y8.2%
EBITDA CAGR 5Y7.2%
Net Profit CAGR 5Y8.5%
NP Growth 1Y3.2%

Historical Growth

Year-by-year revenue, profitability, and cash flow (β‚Ή Crores, last 10 years)

YearRevenueOp. IncomeNet ProfitCFOFCFROERev Growth 1YNP Growth 1Y
Mar 2025β‚Ή2.39 K Crβ€”β‚Ή486.00 Crβ€”β€”17.2%4.6%3.2%
Mar 2024β‚Ή2.28 K Crβ€”β‚Ή471.00 Crβ€”β€”20.2%5.6%0.9%
Mar 2023β‚Ή2.16 K Crβ€”β‚Ή467.00 Crβ€”β€”21.8%1.8%11.5%
Mar 2022β‚Ή2.12 K Crβ€”β‚Ή419.00 Crβ€”β€”20.4%12.6%19.0%
Mar 2021β‚Ή1.89 K Crβ€”β‚Ή352.00 Crβ€”β€”46.7%22.6%12.5%
Mar 2020β‚Ή1.54 K Crβ€”β‚Ή313.00 Crβ€”β€”77.9%73.5%59.7%
Mar 2019β‚Ή886.00 Crβ€”β‚Ή196.00 Crβ€”β€”222.7%β€”β€”
Mar 2018β‚Ή0.00β€”β‚Ή0.00β€”β€”0.0%β€”β€”

Financial Statements

Income statement, balance sheet, and cash flow (β‚Ή Crores, as reported)

Consolidated Figures in USD Millions.

Unnamed: 0Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025TTM
Revenue / Net Sales08861,5371,8852,1232,1612,2832,3872,481
Total Expenses06381,0641,2941,5061,5181,6081,7021,741
EBIT / Operating Profit0248473592617643675684740
OPM %-4%28%31%31%29%30%30%29%30%
Other Income001101428113344
Finance Costs013488281224
Depreciation & Amortisation01929333842536167
Profit Before Tax0228421471565629631654714
Tax %4,200%14%26%25%26%26%25%26%-
Net Profit / PAT0196313352419467471486530
EPS (β‚Ή)-430997.861,597.37358.7434.1738.1138.4339.6343.27
Dividend Payout %0%0%0%0%61%110%59%13%-

Peer Comparison

Healthcare sector peers, ranked by market cap

CompanyMarket CapRevenueP/EP/BEV/EBITDARev G 1Y
ALIVUS LIFE SCIENCES LIMITEDthis co.β‚Ή10.78 K Crβ‚Ή2.39 K Cr20.303.5715.174.6%
Sun Pharmaceutical Industries Ltd.β‚Ή4.15 L Crβ‚Ή23.00 K Cr88.7017.4372.3013.5%
Divi's Laboratories Ltd.β‚Ή1.71 L Crβ‚Ή9.20 K Cr67.9011.1367.2120.0%
Torrent Pharmaceuticals Ltd.β‚Ή1.33 L Crβ‚Ή9.68 K Cr62.5015.7645.6413.5%
Cipla Ltd.β‚Ή1.17 L Crβ‚Ή19.05 K Cr22.503.5119.3314.9%
Apollo Hospitals Enterprises Ltd.β‚Ή1.05 L Crβ‚Ή8.20 K Cr75.0011.2854.4412.8%
Max Healthcare Institute Limitedβ‚Ή1.00 L Crβ‚Ή2.66 K Cr144.0011.7696.8413.8%
Industry Averageβ€”β‚Ή3.29 K Cr98.638.1165.5020.2%

Learn while you research

Hand-picked academy chapters to deepen your understanding of ALIVUS LIFE SCIENCES LIMITED and the metrics that matter.

Browse the full Equiscale Academy